Managing secondary glaucoma due to intravitreal steroids

Conferences|GLAUCOMA 360

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

See more Glaucoma 360 coverage

Related Videos
Related Content

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Researchers uncover therapeutic target to aid in glaucoma treatment

March 13th 2023

Sight Sciences launching new series of surgical system

March 9th 2023

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Researchers uncover therapeutic target to aid in glaucoma treatment

March 13th 2023

Sight Sciences launching new series of surgical system

March 9th 2023

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Impact of prior authorization for cataract surgery

August 16th 2021

Researchers uncover therapeutic target to aid in glaucoma treatment

March 13th 2023

Sight Sciences launching new series of surgical system

March 9th 2023
© 2023 MJH Life Sciences

All rights reserved.